Gabapentin for relief of spasticity associate with multiple sclerosis

American Journal of Physical Medicine and Rehabilitation

Volumn 77, Issue 5, 1998, Pages 451-454

  Dunevsky, Anna ^a   Perel, Allan B ^b  

^a Jewish Medical Center   (United States)

^b STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

Antispasticity Drug; Gabapentin; Multiple Sclerosis; Spasticity

Indexed keywords

DRUG PRODUCTS; DRUG THERAPY;

ANTISPASTICITY DRUG; MULTIPLE SCLEROSIS;

FUNCTIONAL ASSESSMENT;

GABAPENTIN;

4 AMINOBUTYRIC ACID BRAIN LEVEL; ADULT; ARTICLE; CASE REPORT; DRUG EFFICACY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; MUSCLE SPASM; RATING SCALE; SPASTICITY;

ACETIC ACIDS; ADULT; AMINES; ANTICONVULSANTS; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PARASYMPATHOLYTICS;

EID: 0032170307     PISSN: 08949115     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002060-199809000-00020     Document Type: Article

References (17)

1. Baum HM, Rothchild BB: The incidence and prevalence of reported multiple sclerosis. Ann Neurol 1981;10:420-428.
2. Young RR: Spasticity: a review. Neurol 1994;44(suppl 9):S12-S20.
3. Young RR, Delwaide PJ: Drug therapy-spasticity. N Engl J Med 1981;304:28-33,96-99.
4. Katz RT, Campaguolo D: Pharmacologic care of the spastic patients, in Katz RT (ed): Spasticity: State of the Art. Review in the American Journal of Physical Medicine and Rehabilitation. Philadelphia, Hanley and Belfus, 1994, vol 8, pp 441-611.
5. Wagstaff AJ, Bryson HM: Tizanidine: a review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997;53:435-452.
6. Katz RT: Management of spasticity, in Braddom RL (ed): Physical Medicine and Rehabilitation, Philadelphia, WB Saunders, 1996, pp 580-604.
7. Terrence CF, Fromm GH: Complication of baclofen withdrawal. Arch Neurol 1981;38:588-589.
8. Leiderman DB: Gabapentin as add-on therapy for refractory partial epilepsy: result of five placebo-controlled trials. Epilepsia 1994;35(suppl 5):S74-S76.
9. Fromm GH: Gabapentin: discussion. Epilepsia 1994;35(suppl 5):S77-S80.
10. McLean MJ: Gabapentin. Epilepsia 1995;36(suppl):S73-S86.
11. Bohannon RW, Smith MB: Interrater reliability on a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67:206-207.
12. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
13. Priebe MM, Sherwood AM: A quantitative study of the effects of gabapentin on spasticity (abstract). J Spinal Cord Med 1996;19:289.
14. Mellick GA, Mellick LB: Gabapentin in the management of reflex sympathetic dystrophy (letter). J Pain Symptom Manage 1995;10:265-266.
15. Segal AZ, Rordorf G: Gabapentin as a novel treatment for postherpetic neuralgia. Neurology 1996;46:1175-1176.
16. Rosner H, Rubin L, Kestenbaum A: Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain 1996;12:56-58.
17. Mueller ME, Gruenthal M, Olson WL, Olson WH: Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil 1997;78:521-524.